Arena Pharma (ARNA) Posts Surprise Q2 Profit of 2c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Arena Pharma (ARNA) PT Cut to $5 at BofA/Merrill Lynch on Weaker Belviq Sales
August 4, 2014 8:54 AM EDTBofA/Merrill Lynch analyst Steve Byrne reiterated an Underperform rating and lowered his price target on Arena Pharma (NASDAQ: ARNA) to $5.00 (from $6.00) following Q2 results citing a weaker Belviq trajectory.
Byrne notse the next key catalyst will be data from the... More
Jefferies Maintains Bullish Stance on Arena Pharma (ARNA) Despite Weaker Belviq Sales
August 4, 2014 7:23 AM EDTJefferies analyst Thomas Wei reiterated a Buy rating and $11 price target on Arena Pharma (NASDAQ: ARNA) following Belviq sales of $9.9m, below our $12.2m estimate.
"We... More
Arena Pharma (ARNA) PT Lowered at Well Fargo
August 1, 2014 1:11 PM EDTWells Fargo maintained a Market Perform rating on Arena Pharma (NASDAQ: ARNA) and reduced its price target to $4.50-$5.00 (from $5.50-$6.50). The change follows Q2 results and lower Belviq sales than expected. Analyst Matthew J. Andrews sees Belviq U.S. commercial... More
